Literature DB >> 15477414

Broad-spectrum CC-chemokine blockade by gene transfer inhibits macrophage recruitment and atherosclerotic plaque formation in apolipoprotein E-knockout mice.

Christina A Bursill1, Robin P Choudhury, Ziad Ali, David R Greaves, Keith M Channon.   

Abstract

BACKGROUND: The CC-chemokines (CKs) recruit monocytes/macrophages to sites of inflammation; several different CC-CKs play a role in the pathogenesis of atherosclerosis. The vaccinia virus expresses a 35-kDa soluble protein (35K) that binds to and inactivates nearly all of the CC-CKs, providing a potentially useful therapeutic strategy for broad-spectrum CC-CK inhibition in atherosclerosis. A recombinant adenovirus encoding soluble 35K (Ad35K) was generated to investigate the effect of 35K gene transfer on atherosclerosis in Western diet-fed apolipoprotein E-knockout (ApoE KO) mice. METHODS AND
RESULTS: ApoE KO mice received tail-vein injections of phosphate-buffered saline, Ad35K, or control adenovirus AdGFP encoding green fluorescence protein. Two weeks after Ad35K gene transfer, atherosclerotic lesion area was significantly reduced in aortic roots by 55% compared with PBS or AdGFP control mice (P<0.05). Furthermore, 35K gene transfer strikingly reduced the macrophage content in aortic root lesions by 85% (P<0.01) and reduced lipid deposition in descending aortas by more than half (P<0.05). By an in vitro chemotaxis assay, plasma and aortic homogenates from 35K gene transfer mice promoted significantly less CC-CK-induced cell migration than did PBS or AdGFP controls.
CONCLUSIONS: These findings show that a single intravenous injection of a recombinant adenovirus encoding the broad-spectrum CC-CK inhibitor 35K can reduce atherosclerosis by inhibiting CC-CK-induced macrophage recruitment in atherosclerotic ApoE KO mice. These experiments suggest that CC-CKs play an important role in atherogenesis and are a rational target for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15477414     DOI: 10.1161/01.CIR.0000145122.58420.CO

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  27 in total

1.  Angiotensin-converting enzyme inhibition down-regulates the pro-atherogenic chemokine receptor 9 (CCR9)-chemokine ligand 25 (CCL25) axis.

Authors:  Joshua Abd Alla; Andreas Langer; Sherif S Elzahwy; Gökhan Arman-Kalcek; Thomas Streichert; Ursula Quitterer
Journal:  J Biol Chem       Date:  2010-05-26       Impact factor: 5.157

2.  Targeting Innate Immunity for CV Benefit.

Authors:  Kathryn J Moore; Mason W Freeman
Journal:  Drug Discov Today Ther Strateg       Date:  2008

Review 3.  Gene therapy for the prevention of vein graft disease.

Authors:  Kevin W Southerland; Sarah B Frazier; Dawn E Bowles; Carmelo A Milano; Christopher D Kontos
Journal:  Transl Res       Date:  2012-12-27       Impact factor: 7.012

4.  Agonistic antibody to angiotensin II type 1 receptor accelerates atherosclerosis in ApoE-/- mice.

Authors:  Weijuan Li; Yaoqi Chen; Songhai Li; Xiaopeng Guo; Wenping Zhou; Qiutang Zeng; Yuhua Liao; Yumiao Wei
Journal:  Am J Transl Res       Date:  2014-11-22       Impact factor: 4.060

5.  The nitroxide radical TEMPOL prevents obesity, hyperlipidaemia, elevation of inflammatory cytokines, and modulates atherosclerotic plaque composition in apoE-/- mice.

Authors:  Christine H J Kim; James B Mitchell; Christina A Bursill; Anastasia L Sowers; Angela Thetford; John A Cook; David M van Reyk; Michael J Davies
Journal:  Atherosclerosis       Date:  2015-03-16       Impact factor: 5.162

Review 6.  Chemokine receptor CCR5: from AIDS to atherosclerosis.

Authors:  K L Jones; J J Maguire; A P Davenport
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

Review 7.  Regulation of atherogenesis by chemokines and chemokine receptors.

Authors:  Wuzhou Wan; Philip M Murphy
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2012-12-07       Impact factor: 4.291

8.  CCR1 and CCR5 promote hepatic fibrosis in mice.

Authors:  Ekihiro Seki; Samuele De Minicis; Geum-Youn Gwak; Johannes Kluwe; Sayaka Inokuchi; Christina A Bursill; Josep M Llovet; David A Brenner; Robert F Schwabe
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

9.  Interactions between human immunodeficiency virus type 1 and vaccinia virus in human lymphoid tissue ex vivo.

Authors:  Christophe Vanpouille; Angélique Biancotto; Andrea Lisco; Beda Brichacek
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

Review 10.  Macrophage differentiation and function in atherosclerosis: opportunities for therapeutic intervention?

Authors:  Howell J Williams; Edward A Fisher; David R Greaves
Journal:  J Innate Immun       Date:  2012-04-27       Impact factor: 7.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.